(S) -VQW-765

(S) -VQW-765 ((S) -AQW-051) is an orally active, selective and effective α7 nicotinic ACh receptor (nAChR) partial agonist. (S) -VQW-765 has potential applications in cognitive disorders related to neurological diseases, such as Alzheimer's disease or schizophrenia[1][2].

Product Specifications

Product Name Alternative

(S) -AQW-051

UNSPSC

12352005

Target

NAChR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/s-vqw-765.html

Purity

98.00

Solubility

10 mM in DMSO

Smiles

CC(C=C1)=CC=C1C2=NC=C(C=C2)O[C@H]3C4CCN(CC4)C3

Molecular Formula

C19H22N2O

Molecular Weight

294.39

References & Citations

[1]Feuerbach D, et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol. 2015 Mar;172 (5) :1292-304. |[2]Mazurov A, et al. Nicotinic acetylcholine receptor modulators[J]. Small Molecule Therapeutics for Schizophrenia, 2015: 213-253.